{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:14:21Z","timestamp":1789193661799,"version":"build-2803163510"},"reference-count":87,"publisher":"American Society for Microbiology","issue":"17","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Influenza is a global health concern, causing death, morbidity, and economic losses. Chemotherapeutics that target influenza virus are available; however, rapid emergence of drug-resistant strains is common. Therapeutic targeting of host proteins hijacked by influenza virus to facilitate replication is an antiviral strategy to reduce the development of drug resistance. Nuclear export of influenza virus ribonucleoprotein (vRNP) from infected cells has been shown to be mediated by exportin 1 (XPO1) interaction with viral nuclear export protein tethered to vRNP. RNA interference screening has identified XPO1 as a host proinfluenza factor where XPO1 silencing results in reduced influenza virus replication. The<jats:named-content content-type=\"genus-species\">Streptomyces<\/jats:named-content>metabolite XPO1 inhibitor leptomycin B (LMB) has been shown to limit influenza virus replication<jats:italic>in vitro<\/jats:italic>; however, LMB is toxic<jats:italic>in vivo<\/jats:italic>, which makes it unsuitable for therapeutic use. In this study, we tested the anti-influenza virus activity of a new class of orally available small-molecule selective inhibitors of nuclear export, specifically, the XPO1 antagonist KPT-335 (verdinexor). Verdinexor was shown to potently and selectively inhibit vRNP export and effectively inhibited the replication of various influenza virus A and B strains<jats:italic>in vitro<\/jats:italic>, including pandemic H1N1 virus, highly pathogenic H5N1 avian influenza virus, and the recently emerged H7N9 strain.<jats:italic>In vivo<\/jats:italic>, prophylactic and therapeutic administration of verdinexor protected mice against disease pathology following a challenge with influenza virus A\/California\/04\/09 or A\/Philippines\/2\/82-X79, as well as reduced lung viral loads and proinflammatory cytokine expression, while having minimal toxicity. These studies show that verdinexor acts as a novel anti-influenza virus therapeutic agent.<\/jats:p><jats:p><jats:bold>IMPORTANCE<\/jats:bold>Antiviral drugs represent important means of influenza virus control. However, substantial resistance to currently approved influenza therapeutic drugs has developed. New antiviral approaches are required to address drug resistance and reduce the burden of influenza virus-related disease. This study addressed critical preclinical studies for the development of verdinexor (KPT-335) as a novel antiviral drug. Verdinexor blocks progeny influenza virus genome nuclear export, thus effectively inhibiting virus replication. Verdinexor was found to limit the replication of various strains of influenza A and B viruses, including a pandemic H1N1 influenza virus strain, a highly pathogenic H5N1 avian influenza virus strain, and a recently emerging H7N9 influenza virus strain. Importantly, oral verdinexor treatments, given prophylactically or therapeutically, were efficacious in limiting lung virus burdens in influenza virus-infected mice, in addition to limiting lung proinflammatory cytokine expression, pathology, and death. Thus, this study demonstrated that verdinexor is efficacious against influenza virus infection<jats:italic>in vitro<\/jats:italic>and<jats:italic>in vivo<\/jats:italic>.<\/jats:p>","DOI":"10.1128\/jvi.01774-14","type":"journal-article","created":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T01:59:55Z","timestamp":1403747995000},"page":"10228-10243","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":107,"title":["Verdinexor, a Novel Selective Inhibitor of Nuclear Export, Reduces Influenza A Virus Replication<i>In Vitro<\/i>and<i>In Vivo<\/i>"],"prefix":"10.1128","volume":"88","author":[{"given":"Olivia","family":"Perwitasari","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuzhen","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Howerth","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Shacham","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics, Inc., Natick, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Landesman","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics, Inc., Natick, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkan","family":"Baloglu","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics, Inc., Natick, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara","family":"McCauley","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics, Inc., Natick, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Tamir","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics, Inc., Natick, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Mark","family":"Tompkins","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Tripp","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"issue":"8","key":"e_1_3_2_2_2","first-page":"1","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010","volume":"59","author":"Fiore AE","year":"2010","unstructured":"FioreAEUyekiTMBroderKFinelliLEulerGLSingletonJAIskanderJKWortleyPMShayDKBreseeJSCoxNJCenters for Disease Control and Prevention (CDC). 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 59(RR-8):1\u201362. http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5908a1.htm.","journal-title":"MMWR Recomm. Rep."},{"key":"e_1_3_2_3_2","first-page":"1","article-title":"Deaths: preliminary data for 2003","volume":"53","author":"Hoyert DL","year":"2005","unstructured":"HoyertDLKungH-CSmithBL. 2005. Deaths: preliminary data for 2003. Natl. Vital Stat. Rep. 53:1\u201348. http:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr53\/nvsr53_15.pdf.","journal-title":"Natl. Vital Stat. Rep."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/430424"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200406040-00001"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200404000-00010"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8627(03)00018-X"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-92165-3_3"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.04.019"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.11.1333"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1002051107"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67338-2"},{"key":"e_1_3_2_13_2","first-page":"1","article-title":"Antiviral agents for the treatment and chemoprophylaxis of influenza\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Fiore AE","year":"2011","unstructured":"FioreAEFryAShayDGubarevaLBreseeJSUyekiTM. 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 60:1\u201324. http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr6001a1.htm.","journal-title":"MMWR Recomm. Rep."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050740"},{"key":"e_1_3_2_15_2","first-page":"1691","volume-title":"Fields virology","author":"Wright PF","year":"2007","unstructured":"WrightPFNeumannGKawaokaY. 2007. Orthomyxoviruses, p 1691\u20131740. In FieldsBNKnipeDMHowleyPM (ed), Fields virology, 5th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.","edition":"5"},{"key":"e_1_3_2_16_2","first-page":"1647","volume-title":"Fields virology","author":"Palese P","year":"2007","unstructured":"PalesePShawML. 2007. Orthomyxoviridae: the viruses and their replication., p 1647\u20131689. In FieldsBNKnipeDMHowleyPM (ed), Fields virology, 5th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.","edition":"5"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.12.017"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature07151"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08760"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08699"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037169"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.12.018"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2009.02.046"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.11-193466"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01532-12"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399401002575"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0854.2005.00263.x"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M303571200"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1998.9329"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2006.09.013"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.1.408-419.2001"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2004.08.012"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003019"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.16.7375-7383.2001"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0854.2001.21002.x"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.219"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.16.9112"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-0674(02)00337-X"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1217203110"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0858"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.415"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12231"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-429506"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.10.036"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-423160"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.115"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2012.09.002"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E12-01-0045"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087585"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20050162"},{"key":"e_1_3_2_51_2","volume-title":"Abstr. 55th Annu. Meet. Am. Soc. Hematol.","author":"Kuruvilla J","year":"2013","unstructured":"KuruvillaJGutierrezMShahBGabrailNBrownPStoneRGarzonRSavonaMBazRMau-SorensenMDavidsMByrdJShachamSRashalTYauCYMcCauleyDSaint-MartinJ-RMcCartneyJLandesmanYKlebanovBPondGOzaAKauffmanMMirzaMR. 2013. Preliminary evidence of anti-tumor activity of selinexor (KPT-330) in a phase I trial of a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with relapsed\/refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), abstr. 90. In Abstr. 55th Annu. Meet. Am. Soc. Hematol., New Orleans, LA."},{"key":"e_1_3_2_52_2","volume-title":"Gastrointestinal Cancers Symposium","author":"Mau-Sorensen M","year":"2013","unstructured":"Mau-SorensenMRazakARMahipalAMahasethHGerecitanoJFShachamSYauCYLassenUShieldsAFMcCauleyDCookseyJTanDSPRashalTShachamELandesmanYPondGOzaAMKauffmanMSiuLLMirzaMR. 2013. Safety and anti-tumor activity of KPT-330, a first-in-class oral XPO1 selective inhibitor of nuclear export\u2014phase I study expanded with colon cancer cohort. Gastrointestinal Cancers Symposium. American Society of Clinical Oncology, San Francisco, CA."},{"key":"e_1_3_2_53_2","volume-title":"Abstr. 55th Annu. Meet. Am. Soc. Hematol.","author":"Savona M","year":"2013","unstructured":"SavonaMGarzonRBrownPYeeKLancetJGutierrezMGabrailNMau-SorensenMBazRShachamSRashalTYauCYMcCauleyDSaint-MartinJ-RMcCartneyJLandesmanYKlebanovBPondGOzaAKauffmanMMirzaMRStoneRM. 2013. Phase I trial of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with advanced acute myelogenous leukemia (AML), poster 1. In Abstr. 55th Annu. Meet. Am. Soc. Hematol., New Orleans, LA."},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-279-3_6"},{"key":"e_1_3_2_55_2","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed LJ","year":"1938","unstructured":"ReedLJMuenchH. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493\u2013497.","journal-title":"Am. J. Hyg."},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/0471729256.mc15g01s3"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1282"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1177\/2211068213491094"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr1013"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2010.12.014"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2010.01.005"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076708"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/35060098"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-1702(01)00263-5"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M413726200"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00563-12"},{"key":"e_1_3_2_67_2","first-page":"1727","article-title":"Novel selective inhibitors of nuclear export attenuate inflammation and prevent bone mineral density loss in multiple preclinical models of rheumatoid arthritis","volume":"65","author":"Hamuza M","year":"2013","unstructured":"HamuzaMLandesmanYKlebanovBKauffmanMShachamSEndresJFoxDAMcCauleyD. 2013. Novel selective inhibitors of nuclear export attenuate inflammation and prevent bone mineral density loss in multiple preclinical models of rheumatoid arthritis. Arthritis Rheum. 65(Suppl 10):1727. (Abstract.).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1089\/0882824041310513"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02374-08"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi050701e"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M808271200"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.212285299"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.micro.52.1.491"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02760-06"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01403-08"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00367-09"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature07975"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.12.016"},{"key":"e_1_3_2_79_2","volume-title":"Abstr. 26th Int. Conf. Antiviral Res.","author":"Boons E","year":"2013","unstructured":"BoonsEVanstreelsEVercruysseTShachamSLandesmanYBalugluETamirSPannecouqueCDaelemansD. 2013. Replication inhibition by small-molecule inhibitors targeting the HIV Rev-CRM1\/XPO1 interaction, abstr 20. Abstr. 26th Int. Conf. Antiviral Res., San Francisco, CA."},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.3.1014"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.6.2269-2284.2000"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.15.5.2689"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.110.3.369"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111559200"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2457"},{"key":"e_1_3_2_86_2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1158\/1541-7786.42.3.1","article-title":"Inhibition of IkappaBalpha nuclear export as an approach to abrogate nuclear factor-kappaB-dependent cancer cell survival","volume":"3","author":"O'Connor S","year":"2005","unstructured":"O'ConnorSShumwaySMiyamotoS. 2005. Inhibition of IkappaBalpha nuclear export as an approach to abrogate nuclear factor-kappaB-dependent cancer cell survival. Mol. Cancer Res. 3:42\u201349. http:\/\/mcr.aacrjournals.org\/content\/3\/1\/42.long.","journal-title":"Mol. Cancer Res."},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000646"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029347"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.01774-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.01774-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T15:50:08Z","timestamp":1689349808000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JVI.01774-14"}},"subtitle":[],"editor":[{"given":"B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":87,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1128\/JVI.01774-14"],"URL":"https:\/\/doi.org\/10.1128\/jvi.01774-14","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"2014-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}